# MDGL catalysts: MADRIGAL PHARMACEUTICALS, INC. PDUFA dates and FDA events

Canonical: https://sec-api.dev/companies/mdgl/catalysts

> MADRIGAL PHARMACEUTICALS, INC. (MDGL) has 12 upcoming catalysts. The next is the Rezdiffra (resmetirom) primary completion, December 2026.

Data as of November 16, 2026 (snapshot 20261116T222116Z). Every date quotes the SEC filing or FDA page it came from. Date precision: exact day, quarter only, month only, year only.

**Free:** every drug page and the next 30 days of the FDA calendar, no account. Calendar API, alerts when a date moves, and full history: https://sec-api.dev/pricing . Free API key: https://sec-api.dev/sign-up?ref=ai-claudebot

## Company

| Field | Value |
| --- | --- |
| Name | MADRIGAL PHARMACEUTICALS, INC. |
| Ticker | MDGL (Nasdaq) |
| SEC CIK | 1157601 |
| SIC | 2834 |
| SEC filings | https://sec-api.dev/companies/mdgl |

## Catalysts

| Date | Event | Ticker | Indication | Status | Source sentence |
| --- | --- | --- | --- | --- | --- |
| March 14, 2024 | [MADRIGAL PHARMACEUTICALS, INC. PDUFA date](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | scheduled | "The FDA granted our request for priority review of our NDA and assigned a Prescription Drug User Fee Act ("PDUFA") date of March 14, 2024." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1157601/000162828025007980/mdgl-20241231.htm)) |
| March 14, 2024 | [Rezdiffra (resmetirom) FDA approval](https://sec-api.dev/pdufa/resmetirom) | MDGL | with noncirrhotic MASH with moderate to advanced liver fibrosis | completed, approved | "Rezdiffra \| resmetirom \| 3/14/2024 \| To treat noncirrhotic non-alcoholic steatohepatitis with moderate to advanced liver scarringPress ReleaseDrug Trials Snapshot" ([FDA novel drug approvals](https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2024)) |
| January 13, 2025 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Fourth quarter and full-year 2024 financial results are preliminary, unaudited, subject to adjustment, and provided as an approximation in advance of the Companys announcement of complete financial results in February 2025." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000119312525004939/d925380dex991.htm)) |
| February 26, 2025 | [Rezdiffra (resmetirom) earnings report](https://sec-api.dev/pdufa/resmetirom) | MDGL |  | completed | "Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2024 Financial Results and Announces New Two-Year Data Demonstrating Potential Benefit of Rezdiffra (resmetirom) in Patients with Compensated MASH Cirrhosis" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000119312525035787/d924231dex991.htm)) |
| May 1, 2025 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Madrigal Pharmaceuticals Reports First-Quarter 2025 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000162828025021314/exhibit991-1q25earningsrel.htm)) |
| August 5, 2025 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Madrigal Pharmaceuticals Reports Second-Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000162828025037596/a2q25pressrelease_final.htm)) |
| November 4, 2025 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Madrigal Pharmaceuticals Reports Third-Quarter 2025 Financial Results and" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000162828025048525/a3q25pressrelease.htm)) |
| February 19, 2026 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Madrigal Pharmaceuticals Reports Fourth-Quarter and Full-Year 2025 Financial Results" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000162828026009476/exhibit991.htm)) |
| Q2 2026 | [MGL-2086 trial start](https://sec-api.dev/pdufa/mgl-2086) | MDGL |  | scheduled | "An Investigational New Drug application ("IND") has been accepted and we plan to start a Phase 1 single ascending dose trial of MGL-2086 in the second quarter of 2026." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm)) |
| May 6, 2026 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Madrigal Pharmaceuticals Reports First-Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000162828026030896/exhibit991-33126earningspr.htm)) |
| Jun 2026 | [MGL-2086 trial start](https://sec-api.dev/pdufa/mgl-2086) | MDGL |  | completed | "In June 2026, we initiated a Phase 1 single ascending dose trial of MGL-2086 in healthy volunteers to assess safety and a dose response." ([SEC Form 10-Q](https://www.sec.gov/Archives/edgar/data/1157601/000162828026050845/mdgl-20260630.htm)) |
| July 30, 2026 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Madrigal Pharmaceuticals Reports Second-Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000162828026050775/exhibit991-63026earningspr.htm)) |
| November 3, 2026 | [MADRIGAL PHARMACEUTICALS, INC. earnings report](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | completed | "Madrigal Pharmaceuticals Reports Third-Quarter 2026 Financial Results and Provides Corporate Updates" ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000162828026069093/exhibit991-93026earningspr.htm)) |
| December 2026 | [Rezdiffra (resmetirom) primary completion](https://sec-api.dev/pdufa/resmetirom) | MDGL | NASH; Cirrhosis, Liver | scheduled | "NCT05500222 (A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05500222)) |
| Dec 2026 to Mar 2027 | [Rezdiffra (resmetirom) topline data readout](https://sec-api.dev/pdufa/resmetirom) | MDGL | NASH; Cirrhosis, Liver | scheduled | "NCT05500222 (A Phase 3 Study to Evaluate the Effect of Resmetirom on Clinical Outcomes in Patients With Well-compensated NASH Cirrhosis (MAESTRO-NASH-OUTCOMES)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2026-12 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT05500222)) |
| 2027 | [MADRIGAL PHARMACEUTICALS, INC. topline data readout](https://sec-api.dev/companies/mdgl/catalysts) | MDGL |  | scheduled | "◦Baseline characteristics of patients from the OLE F4c cohort are similar to patients enrolled in the ongoing MAESTRO-NASH OUTCOMES trial which is expected to read out topline data in 2027." ([Press release filed with the SEC (EX-99)](https://www.sec.gov/Archives/edgar/data/1157601/000162828026009476/exhibit991.htm)) |
| 2027 | [Ervogastat trial start](https://sec-api.dev/pdufa/ervogastat) | MDGL |  | scheduled | "In addition, we expect to initiate a Phase 2 combination trial with ervogastat and resmetirom in 2027 following discussions with the FDA." ([SEC Form 10-K](https://www.sec.gov/Archives/edgar/data/1157601/000162828026009514/mdgl-20251231.htm)) |
| March 2027 | [Rezdiffra (resmetirom) primary completion](https://sec-api.dev/pdufa/resmetirom) | MDGL | Non-Alcoholic Fatty Liver Disease | scheduled | "NCT04951219 (A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04951219)) |
| Mar to Jun 2027 | [Rezdiffra (resmetirom) topline data readout](https://sec-api.dev/pdufa/resmetirom) | MDGL | Non-Alcoholic Fatty Liver Disease | scheduled | "NCT04951219 (A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Patients With Non-alcoholic Fatty Liver Disease (NAFLD), MAESTRO-NAFLD-Open-Label-Extension (MAESTRO-NAFLD-OLE)): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2027-03 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT04951219)) |
| January 2028 | [Rezdiffra (resmetirom) primary completion](https://sec-api.dev/pdufa/resmetirom) | MDGL | NASH - Nonalcoholic Steatohepatitis | scheduled | "NCT03900429 (A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03900429)) |
| Jan to Apr 2028 | [Rezdiffra (resmetirom) topline data readout](https://sec-api.dev/pdufa/resmetirom) | MDGL | NASH - Nonalcoholic Steatohepatitis | scheduled | "NCT03900429 (A Phase 3 Study to Evaluate the Efficacy and Safety of MGL-3196 (Resmetirom) in Patients With NASH and Fibrosis): Overall Status ACTIVE_NOT_RECRUITING; Phase PHASE3; Primary Completion 2028-01 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT03900429)) |
| August 2028 | [Rezdiffra (resmetirom) primary completion](https://sec-api.dev/pdufa/resmetirom) | MDGL | MASH - Metabolic Dysfunction-Associated Steatohepatitis | scheduled | "NCT07335601 (Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07335601)) |
| Aug to Nov 2028 | [Rezdiffra (resmetirom) topline data readout](https://sec-api.dev/pdufa/resmetirom) | MDGL | MASH - Metabolic Dysfunction-Associated Steatohepatitis | scheduled | "NCT07335601 (Study to Evaluate Resmetirom in Post-Liver Transplant Patients With MASH): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2028-08 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07335601)) |
| July 2029 | [Rezdiffra (resmetirom) primary completion](https://sec-api.dev/pdufa/resmetirom) | MDGL | MASH; MASH - Metabolic Dysfunction-Associated Steatohepatitis | scheduled | "NCT07763015 (Study of Resmetirom in Children and Adolescents With MASH): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07763015)) |
| Jul to Oct 2029 | [Rezdiffra (resmetirom) topline data readout](https://sec-api.dev/pdufa/resmetirom) | MDGL | MASH; MASH - Metabolic Dysfunction-Associated Steatohepatitis | scheduled | "NCT07763015 (Study of Resmetirom in Children and Adolescents With MASH): Overall Status RECRUITING; Phase PHASE2; Primary Completion 2029-07 (ESTIMATED); Lead Sponsor Madrigal Pharmaceuticals, Inc.." ([ClinicalTrials.gov](https://clinicaltrials.gov/study/NCT07763015)) |

## Drugs

- [Ervogastat](https://sec-api.dev/pdufa/ervogastat): 
- [MGL-2086](https://sec-api.dev/pdufa/mgl-2086): 
- [Rezdiffra (resmetirom)](https://sec-api.dev/pdufa/resmetirom): with noncirrhotic mash with moderate to advanced liver fibrosis, with mash with moderate to advanced liver fibrosis, with noncirrhotic mash with moderate to, with, MASH - Metabolic Dysfunction-Associated Steatohepatitis, Non-Alcoholic Fatty Liver Disease, NASH - Nonalcoholic Steatohepatitis, MASH

## Feeds and downloads

- Subscribe (iCal): https://sec-api.dev/companies/mdgl/catalysts.ics
- Next 30 days as CSV: https://sec-api.dev/fda-calendar.csv . JSON: https://sec-api.dev/fda-calendar.json . All events (iCal): https://sec-api.dev/fda-calendar.ics
- New or moved PDUFA dates: https://sec-api.dev/pdufa-dates/feed.xml (RSS), https://sec-api.dev/pdufa-dates/feed.json (JSON Feed)
- FDA approvals: https://sec-api.dev/fda-approvals-today/feed.xml (RSS), https://sec-api.dev/fda-approvals-today/feed.json (JSON Feed)
- License: CC BY 4.0 for the public 30-day window (https://sec-api.dev/biotech/license.txt). Full history: https://sec-api.dev/pricing

## Cite this page

sec-api.dev. "MDGL catalysts: MADRIGAL PHARMACEUTICALS, INC. PDUFA dates and FDA events." Biotech catalyst calendar, data as of November 16, 2026 (snapshot 20261116T222116Z). https://sec-api.dev/companies/mdgl/catalysts

```bibtex
@misc{secapidev_companies_mdgl_catalysts_20261116,
  title        = {MDGL catalysts: MADRIGAL PHARMACEUTICALS, INC. PDUFA dates and FDA events},
  author       = {{sec-api.dev}},
  year         = {2026},
  month        = {nov},
  howpublished = {\url{https://sec-api.dev/companies/mdgl/catalysts}},
  note         = {Biotech catalyst calendar, data as of 2026-11-16, snapshot 20261116T222116Z. Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source.}
}
```

```json
{"type":"dataset","id":"secapidev_companies_mdgl_catalysts_20261116","title":"MDGL catalysts: MADRIGAL PHARMACEUTICALS, INC. PDUFA dates and FDA events","publisher":"sec-api.dev","URL":"https://sec-api.dev/companies/mdgl/catalysts","issued":{"date-parts":[[2026,11,16]]},"version":"20261116T222116Z","license":"https://creativecommons.org/licenses/by/4.0/","note":"Compiled from SEC EDGAR filings, FDA and ClinicalTrials.gov; each date quotes its source."}
```

---
Independent. Not affiliated with, endorsed by, or sponsored by the U.S. Food and Drug Administration or the U.S. Securities and Exchange Commission. Dates are as stated by sponsors and FDA; the FDA can act before or after a target date. Not investment advice.
